secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001104659-25-110862
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics announces CNTY-813 T1D program; Q3 net loss $34.4M, cash $132.7M
--------------------------------------------------------------------------------

- CNTY-813 is iPSC-derived beta islet therapy for T1D; preclinical data show reversal of diabetes in mouse models.
- IND-enabling studies for CNTY-813 to start by year-end 2025; IND submission planned as early as 2026.
- Q3 2025 net loss $34.4M vs $31.2M in Q3 2024; R&D expenses down to $22.5M from $27.2M.
- Cash and investments $132.7M as of Sep 30, 2025; estimated cash runway into Q4 2027.
- Discontinuing company-sponsored CALiPSO-1 trial; continuing CARAMEL IST with data expected Dec 5, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465925110862/0001104659-25-110862-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465925110862/tm2530897d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-110862

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer